Arrhythmias & electrophysiologySecondary analysis
Effect of Weight Loss Amplitude Combined with Antiarrhythmic Drugs on Atrial Fibrillation Freedom, as compared to Catheter Ablation: A Sub-Analysis of the PRAGUE-25 Trial
- Secondary analysis of the PRAGUE-25 randomised trial
- per-protocol analysis
Authors' conclusion
In obese patients, the maintenance of SR on AADs is related to the level of weight reduction. The efficacy of AADs in obese patients with a significant weight loss at 12-months follow-up is close to catheter ablation, although the overall AF burden is still non-significantly higher.
Study context
- Population
- Patients with atrial fibrillation (AF) and BMI 30–40per-protocol
- Participants
- 99 / 28 / 27 / 28
- Comparison
- Lifestyle modification (LFM)+AAD by weight-reduction tertile vs catheter ablation (CA)
- CAn = 99reference
- LFM+AAD >8.3%n = 28
- LFM+AAD 3.1-8.1%n = 27
- LFM+AAD <3.1%n = 28
- Primary endpoint
- AF burden
- Follow-up
- 12 months after randomization
Primary result
As reported in the abstract
12 months
CA
0
IQR 0–0
LFM+AAD >8.3%
0%
IQR 0–11.
LFM+AAD 3.1-8.1%
3.5%
IQR 0–52
LFM+AAD <3.1%
1
IQR 0–47
P = 0.17
Original publication
Effect of Weight Loss Amplitude Combined with Antiarrhythmic Drugs on Atrial Fibrillation Freedom, as compared to Catheter Ablation: A Sub-Analysis of the PRAGUE-25 Trial. Europace. Published 20 January 2026. doi:10.1093/europace/euag013
Summarised from the published abstract; every number is checked against it